Skip to main content
Premium Trial:

Request an Annual Quote

EiRx, BioMérieux Pen PGx Alliance to Validate Each Other’s Dx, Rx Biomarkers

NEW YORK (GenomeWeb News) — EiRx Therapeutics and BioMérieux today said they plan to validate the diagnostic and therapeutic potential of their candidate tumor markers.
Terms of the alliance call for BioMérieux to see if proteins in EiRx’s biomarker panel can become components in new diagnostics for colorectal cancer. Meanwhile, EiRx will use its siRNA-driven platform to test BioMérieux’s colorectal biomarker panel as targets for new drug therapies.
During the evaluation phase of the collaboration, which will last up to 18 months, EiRx has granted BioMérieux an exclusive option to license and “exploit” diagnostic applications of its biomarker intellectual property. 
Similarly, BioMérieux has granted EiRx an exclusive option to license and “exploit” therapeutic applications of its own IP, and said it will develop companion diagnostics for any drug candidates developed by EiRx against targets proposed by BioMérieux. 
Financial details of the agreement were not disclosed.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.